Research Projects

Health policy, especially pharmaceutical policy

-   Benefit-Risk and cost-Effectiveness Assessment of Tuberculosis treatments using Healthcare bigdata platform (BREATH study), 2020-2022

»      Claims data analysis on outcomes resulting from the change in tuberculosis management policy

»      Cost-effectiveness analysis of improving patients’ adherence to tuberculosis treatment using real-world data

-   The current usage of generic drugs according to the change in bioequivalence tests regulation, 2019

-   Estimating the price elasticity of demand for off-patent drugs using national claims cohort data, 2016

-   Multi-Criteria Decision Analysis (MCDA) for reimbursement decision-making in healthcare by eliciting preference using AHP (Analytical Hierarchy Process), SWING, and DCE (Discrete Choice Experiments): case study, 2014

-   Case study of risk-benefit assessment for cardio-vascular drugs by using AHP, DCE and network meta-analysis, 2013

-   Development of a new model for benefit-risk assessment of medicines in South Korea, 2012

Economic evaluation

-       Pegzilarginase for treating arginase-1 deficiency. [Review of ID4029], 2024-2025

-       Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [Review of ID3959], 2025

-       Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [Review of ID6256], 2025

-       Effectiveness of psychosocial interventions for adults with substance use disorder that have a co-occurring mental health disorder: an umbrella review and illustrative cost-effectiveness analysis, 2024

-       Evaluation of public health impact of HPV vaccination and related healthcare cost for older adults and immunocompromised patients in Korea, 2024-2025

-       Sparsentan for treating primary IgA nephropathy [Review of ID6308], 2024

-       Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [Review of ID6405], 2024

-       Isatuximab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. [Review of TA658], 2023

-       Abaloparatide for the treatment of osteoporosis in postmenopausal women at increased risk of fracture [ID882], 2023-2024

-       Economic Evaluation of Novel Immunotherapies for Relapsed or Refractory Multiple Myeloma, 2023-2024

-       Economic Evaluation of Oral Antiviral Treatments in High-risk Patients with SARS-CoV-2, 2023

-       Cost-effectiveness analysis of siRNA-based Lipid-lowering Therapy in Atherosclerotic cardiovascular disease, 2023

-   Cost minimization analysis for Combination vaccines of DTaP, 2022

-   Gastrointestinal protection using proton-pump inhibitor in patients
who required oral anticoagulants – cost-effectiveness analysis, 2021-2026

-   Cost-effectiveness analysis of abemaciclib in breast cancer, 2021-2022

-   Efficacy, stability, and cost-effectiveness of multifocal intraocular lens cataract surgery for presbyopia correction, 2020-2021

-   Cost-effectiveness analysis of tafamidis in transthyretin amyloid cardiomyopathy, 2020

-   Cost-effectiveness analysis of PARP inhibitor in breast cancer: Markov model, 2019-2020

-   Cost-effectiveness analysis of a chimeric antigen receptor T-cell treatment in diffuse large B-cell lymphoma: Markov model, 2019-2020

-   Cost-effectiveness analysis of immune-oncology in metastatic Merkel cell carcinoma: Partitioned survival model, 2018-2019

-   Cost-effectiveness analysis in hepatocellular carcinoma in Japan, 2018

-   Cost-effectiveness analysis of JAK inhibitor in rheumatoid arthritis: Discrete event simulation, 2017

-   Cost-effectiveness analysis in ER+, HER2-, advanced breast cancer: a Markov model and partitioned survival model, 2016

-   Cost-effectiveness analysis of stem cell in acute myocardial infarction: a Markov model, 2015

-   Cost-effectiveness analysis of levodopa/carbidopa intestinal gel: a Markov model, 2014

-   Cost-effectiveness of enzalutamide in the treatment of patients with metastatic castration-resistant prostate cancer previously treated with docetaxel in Korea: A Markov model, 2013

Outcomes research using claims data

-   Trends in use of prophylaxis, joint-related outcomes and healthcare utilization in patients with hemophilia A, 2022-2023

-   Real-world evidence of brigatinib in 2l after crizotinib using claims data in South Korea, 2022-2023

-   New treatment criteria for chronic hepatitis B without considering alanine aminotransferase levels to prevent hepatocellular carcinoma, 2021-2023

-   Burden of Illness of locally advanced or metastatic non-small cell lung cancer in South Korea, 2021-2022

-   A non-interventional retrospective observational study of a real-world treatment pattern and disease burden among HR+, HER2- advanced or metastatic breast cancer in Korea, 2021-2022

-   A retrospective cohort analysis to understand the treatment pattern and burden of Rheumatoid Arthritis in Korea, 2019

-   A retrospective cohort study on type 2 diabetes patient with basal insulin initiation and intensification in Korea, 2018-2019

-   A retrospective cohort study on Bleeding and Ischemic event rate in patients using P2Y12-Inhibitors after PCI in Korea, 2018

-   Healthcare resource utilization and treatment patterns in insomnia patients using the JMDC database, 2018

-   Healthcare resource utilization and treatment patterns in diabetic kidney disease patients using the MDV database, 2017

-   Healthcare resource utilization and treatment patterns in adults with moderate to severe psoriasis initiating treatment with a biologic in South Korea: a descriptive study using the Korean health insurance database, 2017

Others

-       Visual outcomes and optical quality of accommodative, multifocal, extended depth of focus, and monofocal intraocular lenses in presbyopia-correcting cataract surgery - a systematic review and network meta-analysis, 2020-2021

-   Indirect treatment comparison of treatments in patients with relapsed/refractory chronic lymphocytic leukemia, 2019

-   Meta-analysis and indirect treatment comparison of biologics in rheumatoid arthritis, 2019

-   Development of patient decision aid for ankylosing spondylitis, 2018-2019

»      Systematic literature review on attributes associated with pharmacological interventions in patients with rheumatic disease

»      Healthcare professional in-depth interview to understand how the current clinical practice is being done and what information is going on between Ankylosing spondylitis patient and physician.

»      Usability and understandability evaluation of Medical Communication Aid (MCA) for patients with ankylosing spondylitis: an in-depth interview

-   Patients’ preference and ease of use of a new growth hormone injection device: A cross-sectional survey in South Korea, 2018-2019

-   The revalidation of the diabetes treatment‑related quality‑of‑life (DTR‑QOL) questionnaire in Japan, 2017

-   Mapping the diabetes treatment‑related quality‑of‑life (DTR-QOL) into EQ-5D in Japanese patients with type 2 diabetes, 2018

-   Progression-free survival with endocrine therapies for advanced breast cancer: a network meta-analysis and indirect treatment comparison, 2014